Survival curves of patients with NPM1-mutated/FLT3-ITD⁻ AML (MLD⁺ vs MLD⁻) from the MLL. (A) No significant differences in OS are observed between NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (gray line) MLD (P = .834). (B) No significant differences in EFS are observed between NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (gray line) MLD (P = .334). (C) No significant differences in OS are observed between normal karyotype NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (gray line) MLD (P = .936). (D) No significant differences in EFS are observed between normal karyotypeNPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (gray line) MLD (P = .150).